BioArk’s Inno DayListe des participants (109)
Date : 11th of November 2014 from 09:00 to 13:45
Location: BioArk, Monthey
“Therapeutic Recombinant Proteins : Next Generation”
Not only recombinant proteins are now considered as excellent therapeutic approaches, but several blockbusters on the market belong to this class of molecules. Of the ten best-selling drugs in 2012, six of them were monoclonal antibody drugs, each with annual sales value exceeding US$5 billion. Nevertheless, the field in terms of innovation is still very open and suggests business opportunities that are currently in development for some of them, or even, entering the market for the others.
On the 11th of November, the speakers of the “Therapeutic Recombinant Proteins - Next Generation” event will cover the wide range of business and innovation opportunities.
- How innovation can support optimization of manufacturing costs?
- Are disposable technologies viable manufacturing solutions?
- What about biosimilar’s development?
- Antibody-drug conjugates - trend or business reality?
- Formulation and analytics - where are the key issues in terms of biopharmaceutical development?
Please find the program here below. The event will be followed by a lunch hosted by BioArk.
Admission is free but registration required until the 7th of November 2014.
BioArk Site manager
|9h00||Arrival of participants|
|9h30||Welcome and opening|
|M. Fernand Mariétan, Chairman of the board of BioArk SA, Monthey|
|10h00|| "Manufacturing of recombinant antibodies and other proteins: Challenges for Innovators
and Biosimilar companies"
|Prof. Florian Wurm, CSO ExcellGene, Monthey and professor at l'EPFL, Lausanne|
|Dr. Maria de Jesus, COO ExcellGene, Monthey|
|10h30||"Importance of analytical methods and formulation for the success of biopharmaceuticals"|
|Prof. Tudor Arvinte, University of Basel and co-founder of Therapeomic Inc.|
|11h00||"Micro-scale tools for the development of monoconal antibody production processes"|
|Dr. Matthieu Stettler, Head of USP, Merck Serono, Corsier-sur-Vevey|
|11h30||Coffee break and Poster-session|
|12h00||"Antibody-Drug Conjugates (ADCs): Specific delivery of cytotoxic payloads"|
|Laurent Ducry, Head of the Bio-Conjugates Process Development Team, Lonza Visp AG|
|12h30||"Smart Implementation of Single-Use Technology"|
|Neil Ross, Marketing Manager, GE Healthcare Life Sciences EMEA|
|13h00||"Recombinant Peptide and Protein Production at the HES-SO Valais"|
|Sarah Wegmüller, HES-SO Valais Wallis, ITV, Sion|
|13h45||Poster-session and lunch|